Skip to main content

Table 2 Rheumatoid Arthritis (RA) Participant Clinical Characteristics

From: Micro-structural bone changes in early rheumatoid arthritis persist over 1-year despite use of disease modifying anti-rheumatic drug therapy

Domain Parameter RA Baseline (n = 30) RA 12-Months (n = 26)
RA Diseases Duration Months Since Diagnosis by a Rheumatologist [mean (SD), min-max] 7.7 (4.9), 1–15* Baseline Only
Rheumatoid Arthritis Blood Markers Anti-cyclic citrullinated protein antibodies (anti-CCP) and/or Rheumatoid Factor (RF) Positive
[# (%)]
22 (73%) Baseline Only
RA Medication Combinations **8 DMARD Only [# (%)] 13 (43%) 22 (85%)
DMARD + Glucocorticoid [# (%)] 15 (50%) 2 (7%)
DMARD + Biologic [# (%)] 1 (3%) 0 (0%)
DMARD + Glucocorticoid + Biologic [# (%)] 0 (0%) 0 (0%)
Single DMARD [# (%)] 14 (47%) 19 (73%)
Double DMARD [# (%)] 7 (23%) 4 (15%)
Triple DMARD [# (%)] 8 (27%) 1 (4%)
*** Glucocorticoids Only [# (%)] 1 (3%) 0 (0%)
**** Biologic Only [# (%)] 0 (0%) 1 (4%)
***** No RA medications [# (%)] 0 (0%) 1 (4%)
RA Medication Timing Months to any DMARD once Diagnosed (n = 29) [mean (SD), min-max] 0.1 (1), −4 to 3 Baseline Only
Months to Glucocorticoids Once Diagnosed (n = 16) [mean (SD), min-max] −1.8 (3), −11 to 1 Baseline Only
Months to Biologic Once Diagnosed (n = 1) 8 Baseline Only
Physical Evaluation – 28-Joint Active (Tender AND Swollen) Joint Count Number participants with NO Tender AND Swollen Joints [n (%)] 9 (30.0) 15 (57.7)
Number participants with at least one Tender AND Swollen Joint [n (%)] 21 (70.0) 11 (42.3)
Number of Tender AND Swollen Joints [mean (SD), min-max] 4.2 (2.3), 1–9 3.6 (3.0), 1–9
Stanford Health Assessment Questionnaire
- Modified (MHAQ) [33]
Disability Index - 0 to 3 [mean (SD), min-max] 0.59 (0.60), 0 to 2.13 0.48 (0.66), 0 to 2.00
Pain Visual Analog Scale (VAS) - 0 to 100 [mean (SD), min-max] 21.2 (16.4), 0 to 65 20.4 (23.3), 0 to 89
Global Functioning VAS - 0 to 100 [mean (SD), min-max] 23.7 (18.8), 1 to 68 18.2 (21.7), 1 to 88
  1. *One RA participant received baseline HR-pQCT scan at 15-months post-diagnosis. The participant attended the baseline evaluation at 12-months post diagnosis, but was sick and could not be re-scheduled due to a planned 3-month vacation
  2. **Non-Biologic Disease-Modifying Anti-Rheumatic Drug (DMARD): Methotrexate, Hydroxychloroquine, Sulfasalazine
  3. ***Glucocorticoid (GC): > = 5 mg / day for ≥3 weeks
  4. ****Biologic anti-TNF: Adalimumab
  5. *****One person moved to an alternative medicine practitioner and stopped all RA prescribed meds
  6. NOTE: Cumulative dosage for any RA medications and medication adherence were was not tracked